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Abstract
Background: Prevalence of obstructive sleep apnea (OSA) in patients with hypertension outnumbers the preva-
lence reported in the general population. Concurrently, majority of patients remain undiagnosed. Given the fact 
that untreated OSA contributes to ineffective hypotensive treatment, and higher rate of complications is ascribed 
to hypertension, early OSA diagnosis and its elimination constitutes one of the key clinical goals. Polysomnography 
comprises a golden standard in sleep apnea diagnosis, however it is a time-consuming and expensive procedure 
which requires hospitalization. Therefore, we assessed the utility of simplified polygraphic (PG) studies in the OSA 
screening of patients with hypertension requiring regular tertiary care.
Material and methods: The study was conducted in the Outpatient Tertiary Care Clinic of the Medical University 
Hospital of Gdansk. We enrolled consecutive patients regardless of OSA symptoms presence (n = 243), as well as 
patients with OSA suspicion (n = 75). A total of 318 patients (39% females) were subjected to ambulatory, one-
night polygraphic study (ApneaLink™). The following signals were recorded: airflow (pressure cannula), respiratory 
movements, and pulse oximetry. Additionally, anthropometrics, Epworth Sleepiness Scale (ESS), selected clinical 
symptoms, and drug-regimen were recorded.
Results: Three hundred and eight (97%) patients completed the study (10 dropouts due to study failure). Patients 
were 57.7 ± 11.5 years old, had BMI = 30.0 ± 5.0 kg/m2, and average ESS = 5.7 ± 4.6. 65.3% of all patients were 
characterized by AHI ≥ 5 (62.2% vs. 74.7% in Random vs. Symptomatic group, respectively; P = 0.49), whereas 
27.6% of patients were diagnosed with AHI ≥ 15 (23.6% in Random group and 40.0% in Symptomatic group). 
In logistic regression analysis, nocturia (> 2) increased the odds of AHI ≥ 30 diagnosis approximately 3.5 times in 
a fully adjusted model.
Conclusions: Our results justify routine polygraphic screening of hypertensive patients requiring tertiary care. 
Abridged medical history may substantially increase the odds for positive screening.
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Introduction
Prevalence of obstructive sleep apnea (OSA) in car-
diovascular patients especially with hypertension dif-
ficult to control outnumbers the prevalence reported 
in the general population [1, 2]. Concurrently, ma-
jority of patients remain undiagnosed. Given the fact 
that untreated OSA contributes to ineffective hypo-
tensive treatment, and higher rate of complications 
is ascribed to hypertension, early OSA diagnosis and 
its elimination constitutes one of the key clinical 
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goals. Polysomnography (PSG) constitutes a gold-
en standard in sleep apnea diagnosis, however, it is 
a time-consuming and expensive procedure which 
requires hospitalization. The portable cardiorespi-
ratory studies (polygraphy) have been proposed as 
a low cost easy to use alternative to PSG [3]. There 
is an ongoing debate whether polygraphic studies 
are suitable for OSA screening in different patient 
subpopulations.
The aim of our study was the assessment of 
polygraphic ambulatory screening in patients requir-
ing regular tertiary care for hypertension treatment.
Materials and methods
Study population consisted of 318 patients (39% 
females) recruited from the Outpatient Tertiary Care 
Hypertension Clinic of Medical University Hospital 
of Gdansk. We enrolled 243 consecutive patients re-
gardless of the presence of OSA symptoms, as well as 
75 patients with OSA suspicion referred for the sleep 
study by cardiovascular medicine specialists. Symp-
toms of sleep apnea differed between patients and 
were subjectively assessed by the referring physician. 
During the ambulatory diagnostic night, the follow-
ing signals were recorded with type IV polygraphy 
(ApneaLink Plus™): airflow, snoring, pulse oximetry, 
chest respiratory movements. The device was oper-
ated by the user, nevertheless, subjects who required 
assistance with the device hook-up were provided 
with help during the procedure. Additionally, we ob-
tained anthropometrical data, drug regimen records 
and selected clinical symptoms such as nocturia, and 
daytime sleepiness quantified with Epworth Sleepi-
ness Scale (ESS).
Statistical analysis
All data were tabulated in MS Excel and comput-
ed in standard statistical package (Statistica v. 12, 
Statsoft, Poland). Continuous variables with normal 
distribution were compared with Student’s t-test and 
one-way ANOVA, where appropriate. Non-normally 
distributed data were analyzed with non-parametric 
tests (Mann-Whitney). Chi-squared test was used 
to compare the number of cases between dichoto-
mized subgroups. Logistic regression analysis was 
performed to assess the role of selected covariates 
with reference to diagnosed OSA. P-value less than 
0.05 was considered valid for all tests.
Results
Three hundred and eight (97%) patients complet-
ed the study. In 10 (3%) patients, the polygraphic 
recording did not meet minimal evaluation criteria, 
thus they were excluded from further analyses (too 
short recordings or signal failure).
Patients were characterized by class 1 obesity (30.0 
± 5.0 kg/m2) and body fat distribution, which sug-
gested abdominal fat accumulation (waist circumfer-
ence was 105 ± 15.0 cm). Detailed clinical character-
istics of the studied group are presented in Table I.
Table I. Clinical characteristics of the study group
  All Random-group Symptomatic-group P value (random  
vs. symptomatic)
Anthropometrics
Males-to-Females ratio 61% : 39% 59% : 41% 67% : 33% 0.22
Age (years) 57.7 ± 11.5 58.6 ± 11.0 55.1 ± 12.7 0.04
BMI [kg/m2] 30.0 ± 5.0 29.5 ± 4.6 31.4 ± 6.1 0.02
Neck [cm] 40.7 ± 4.9 39.6 ± 4.6 41.6 ± 5.1 0.01
Waist [cm] 105.0 ± 15.0 102.4 ± 14.3 107.1 ± 15.5 0.06
Hips [cm] 110.6 ± 13.2 108.7 ± 9.4 112.3 ± 11.3 0.04
No. of hypotensive drugs 2.8 ± 1.4 2.8 ± 1.5 2.9 ± 1.3 0.65
Fraction of patients  with ≥ 3 hypotensive drugs 58% 58% 58% 0.97
Nocturia 1.3 ± 1.2 1.3 ± 1.3 1.2 ± 1.2 0.60
Nocturia > 2 15% 14% 15% 0.87
Nocturia > 1 38% 40% 36% 0.63
ESS 5.7 ± 4.6 4.4 ± 3.6 7.1 ± 5.2 0.001
ESS ≥ 10 20% 13% 28% 0.02 
Data presented as means ± SD; N or per-cent (%). P values for comparisons between Random- vs. Symptomatic-groups
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Discussion
There are 2 main findings in our study. First, routine 
medical history taken in cardiovascular outpatient 
clinic which includes records of nocturia has the ca-
pacity to accurately identify patients with suspicion 
of OSA. Second, given the epidemiological burden, 
regular polygraphic ambulatory screening of tertiary 
care hypertensive patients appears to be a reasonable 
strategy in the comprehensive clinical management. 
Based on this approach, approximately one third of 
patients with hypertension requiring tertiary care 
may be eligible to OSA-treatment commencement, 
without further delay.
Our study supports the concept of simplified 
screening for OSA in the setting of tertiary care 
hypertension outpatient clinic. Based on the pa-
Figure 1. AHI-groups distribution depending on the presence of 
sleep apnea symptoms
Basic polygraphic characteristics were as follows: 
average AHI in the studied group was 12.8 ± 15.2 
(10.6 ± 11.1 vs. 19.7 ± 22.5 in Random vs. Symp-
tomatic-group, respectively; P = 0.01). 65.3% of 
all patients were characterized by AHI ≥ 5 (62.2% 
vs. 74.7% in Random vs. Symptomatic group, re-
spectively; P = 0.49). With reference to polygraphic 
sleep studies recommendations, low probability of 
sleep apnea (AHI < 10) was present in 64% (65% 
vs. 52% in Random vs. Symptomatic group, respec-
tively; P = 0.049). Twenty-seven point six percent 
of patients were diagnosed with AHI ≥ 15 which 
corresponds to high-likelihood of sleep-apnea dia-
gnosis and is consistent with moderate-to-severe 
disease based on PSG (23.6% vs. 40.0% in Random 
vs. Symptomatic group, respectively; P < 0.01). De-
tailed distribution of AHI-subgroups is presented 
in Figure 1.
58% of all patients were treated with 3 or more 
hypotensive drugs. The number of administrated 
blood-lowering drugs varied considerably depending 
on AHI-group, ANOVA; P < 0.01 (Fig. 2).
Data related to nocturia were obtained in 46% of 
the entire group. The distribution of nocturia severi-
ty with relation to AHI-subgroups is summarized 
in Figure 3. Excessive night-time voiding (> 2) was 
associated with approximately 3.5-fold increased 
odds for having been diagnosed with the highest 
AHI (≥ 30), and adjustment to several covariates 
did not alter this relationship (R2 = 0.29; P < 0.001, 
for the fully-adjusted logistic regression model (Ta-
ble II, III).
Epworth Sleepiness Scale (ESS) was completed by 
156 patients (50.6%). Excessive daytime sleepiness 
(≥ 10 pts.) was noted in 20.4% (12.8% vs. 27.8% 
in Random and Symptomatic-groups, respectively; 
P = 0.02).
Figure 2. Blood-lowering pharmacological treatment with relation 
to sleep apnea severity. One-way ANOVA; P = 0.009
Caption: Bars represent an average number of administered hypo-
tensive drugs and whiskers standard error of the mean. P-values 
for post-hoc Dunnett test vs. AHI < 5 group
Figure 3. Number of night-time voiding with reference to AHI-
group. Mann-Whitney test, P = 0.048
Caption: Bars represent Medians and whiskers 3rd quartile
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tient-operated, ambulatory cardiorespiratory 
polygraphic recordings, approximately half of the 
tertiary-care hypertensive population is characterized 
by low probability of OSA, conversely, one third of 
them is eligible for the introduction of OSA treat-
ment without any further delay. This percentage may 
be further increased by complementary full polysom-
nographic recordings, as the polygraphic studies, by 
definition, are characterized by approximately 30% 
lower respiratory indices [4]. Additionally, abridged 
medical history which is focused on selected sleep 
apnea symptoms may substantially increase the ac-
curacy of OSA-patients identification.
Nocturia
Episodes of night-time voiding disrupt sleep conti-
nuity which in turn worsens sleep quality, and may 
affect patients’ daytime performance. Nocturia, the 
symptom which is rarely associated with OSA in 
everyday clinical and ambulatory practice, appears 
to be a very potent marker of undiagnosed sleep dis-
ordered breathing. Commonly, nocturia is associated 
with several chronic medical conditions in adult pop-
ulation such as heart failure, benign prostate hyper-
plasia, or diabetes mellitus, however, OSA is rarely 
taken under consideration in the differential diagno-
sis. Interestingly, recent analyses identify nocturia as 
an independent predictor of all-cause mortality [5]. 
Nocturia may reflect the severity of sleep apnea [6] 
and it may also be ameliorated by OSA reversal (by 
means of continuous positive airway pressure; CPAP) 
[7, 8]. Our data showed that night-time voiding 
greater than 2 times is associated with the increased 
odds for the presence of undiagnosed severe sleep 
apnea in a random group of patients who regularly 
attend tertiary care out-patient hypertension clinic. 
In different logistic regression models, nocturia (> 2) 
increased the odds of AHI ≥ 30 diagnosis about 3.5 
times (Table II). Interestingly, the adjustment for 
different covariates (including alfa-blocker use which 
itself may considerably affect severity of nocturia) did 
not substantially alter the outcome (Table II and III).
Hypertension control
By definition, patients requiring 3 or more 
blood-lowering drugs including diuretic are conside-
red drug-resistant to standard treatment [9, 10]. 
Although the prevalence of such condition is usually 
difficult to estimate precisely (up to 15% depending 
on the subpopulation assessed) [11], the presence 
of truly resistant hypertension is relatively low and 
closely depends on patients’ compliance. In our co-
hort, 58% of screened patients were treated with 
3 or more hypotensive drugs (Table I). This may 
not be directly translated to resistant hypertension 
diagnosis, nevertheless it appears to be a very high 
Table II. Role of nocturia (> 2 times) in the prediction of severe sleep apnea. Logistic regression analysis
  R2 P-value for the 
model 
OR Lower 95% CI Upper 95% CI P value 
Model #1 0.06 0.02 3.62 1.32 9.98 0.01
Model #2 0.09 0.02 3.62 1.26 10.40 0.02
Model #3 0.19 < 0.001 3.71 1.23 11.17 0.02
Model #4 0.19 0.002 3.75 1.24 11.32 0.02
Model #5 0.29 < 0.001 3.47 1.09 11.05 0.03
OR — odds ratio
Models adjusted for: 
#1 – unadjusted
#2 — nocturia > 2 + alfa-blockers use 
#3 — nocturia > 2 + alfa-blockers use + BMI > 27 kg/m2 
#4 — nocturia > 2 + alfa-blockers use + BMI > 27 kg/m2 + age > 60 years old
#5 — nocturia > 2 + alfa-blockers use + BMI > 27 kg/m2 + age > 60 years old + male sex
Table III. Odds ratios for the fully adjusted model (Model No. 5). Logistic regression analysis R2 = 0.29; P < 0.001
  OR Lower 95% CI Upper 95% CI P value
Nocturia (> 2) 3.47 1.09 11.05 0.03
Alpha-blockers use 1.13 0.37 3.48 NS
Male sex 9.21 1.76 48.17 0.01
BMI greater than 27 kg/m2 9.04 1.12 73.84 0.04
Age greater than 60 years old 1.83 0.59 5.67 NS
OR — odds ratio
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rate even for patients requiring tertiary care. Such 
phenomenon may be partly explained by two main 
issues. First, following the recommendation for the 
fixed-dose therapies, tertiary care physicians are more 
likely to administer such formulas. Second, there is 
a considerable number of patients who were pre-
viously undiagnosed with sleep apnea, which may 
conceivably add to their blood pressure load. We 
report that about 40% of patients who are regular 
attendants of our Hypertension Centre may be di-
agnosed with moderate-to-severe disease (Fig. 1). All 
of the hypertension management guidelines issued 
in the last decade underscored the need for sleep-dis-
ordered breathing screening and treatment in almost 
every patient evaluated for blood-lowering treatment 
failure [1, 10, 12, 13]. As there is an incremental 
relationship between severity of apnea and the risk 
for hypertension observed in the general population 
[14, 15], also severity of OSA may contribute to 
blood-lowering treatment difficulties in hyperten-
sives [16]. Based on our clinical data, we showed 
that patients with AHI ≥ 30 require significantly 
higher number of hypotensive drugs comparing to 
their counterparts (Fig. 2), and the presence of OSA 
symptoms did not alter this relationship (Table I). 
This finding underscores wide screening of sleep ap-
nea even in minimally symptomatic patients. Given 
the fact, that CPAP treatment considerably modifies 
the discussed association [17], as well as there is an 
evident CPAP-related blood pressure lowering effect 
[18], a prompt OSA screening in corresponding pop-
ulations should be endorsed.
Obesity
The role of obesity in the development of sleep-dis-
ordered breathing has been well established [19]. In 
our cohort, average BMI for the entire study group 
equaled 30.0 ± 5.0 kg/m2 which is consistent with 
class 1 obesity diagnosis. There was a difference in 
BMI recorded in Random vs. Symptomatic groups: 
29.5 ± 4.6 vs. 31.4 ± 6.1 kg/m2, respectively (Table I). 
Although the mean difference in BMI between the 
two subgroups was rather modest (approx. 2 kg/m2), 
the logistic regression pointed at the assessment of the 
influence of different covariates on the development 
of sleep apnea further confirmed its independent role 
(BMI > 27 kg/m2 was associated with increased odds 
for the diagnosis of AHI ≥ 30 by approx. 9 times) 
(Table III). It is worth mentioning that American 
guidelines on hypertension management (JNC7) is-
sued more than a decade ago stressed the role of an 
increased BMI as an accurate indicator for suspected 
OSA in the hypertensive population [1]. Experts of 
JNC7 recommended thorough screening for OSA, 
even in relatively lean hypertensive patients (BMI 
greater than 27 kg/m2 which is consistent with the 
diagnosis of overweight). In line with JNC 7, re-
cent guidelines of the Polish Society of Hypertension 
(PTNT) also characterized hypertensives requiring 
further diagnosis of sleep-disordered breathing. Of 
more, the metabolic syndrome, a condition mainly 
determined by comorbid obesity is emphasized by 
PTNT as a valuable pre-screening tool in OSA-sus-
picion [10].
Strengths and limitations
Our study did not aim at comparing of the 
polygraphic recordings vs. attended polysomnogra-
phy. However, it was shown elsewhere that portable 
devices fairly reflect the PSG results, accurately strat-
ify patients [20–22], as well as they are sufficiently 
reliable as for the decision on CPAP treatment com-
mencement [23]. There are unquestionable advan-
tages of ambulatory screening over attended PSG. 
Most important such procedure does not require 
adaptation night as patients sleep in their natural en-
vironment. Sleep societies endorse screening for OSA 
with polygraphic devices only in selected subpopula-
tions [24], however, cardiovascular entities are more 
likely to support its use as an effective pre-screening 
tool in a wide spectrum of CV-patients [10]. As we 
observed screening rate (AHI ≥ 5) in more than 
70% of hypertensive patients, our data support such 
strategy. Nevertheless, it is critical to remember that 
portable monitoring devices have the capacity to 
confirm OSA, but are not sufficient to exclude any of 
the sleep-disordered breathing, especially in patients 
complaining of OSA-symptoms.
Conclusions
We conclude that frequent nocturia may serve as a po-
tent marker of undiagnosed severe sleep apnea. Our 
data also support the concept of ambulatory polygraph-
ic screening for OSA even in minimally symptomatic 
patients requiring hypertension tertiary care.
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